NewAmsterdam Pharma
Quick facts
Phase 3 pipeline
- Monotherapy ezetimibe · Cardiovascular
Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter. - Monotherapy obicetrapib · Cardiovascular
Obicetrapib inhibits CETP (cholesterol ester transfer protein) to increase HDL cholesterol and reduce LDL cholesterol levels.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about NewAmsterdam Pharma
What is NewAmsterdam Pharma's pipeline?
NewAmsterdam Pharma has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Monotherapy ezetimibe, Monotherapy obicetrapib.
Related
- Sector hub: All tracked pharma companies